Satellos Bioscience Management
Management criteria checks 1/4
Satellos Bioscience's CEO is Frank Gleeson, appointed in Mar 2018, has a tenure of 6.75 years. total yearly compensation is CA$1.93M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 3.35% of the company’s shares, worth €2.16M. The average tenure of the management team and the board of directors is 1.6 years and 3 years respectively.
Key information
Frank Gleeson
Chief executive officer
CA$1.9m
Total compensation
| CEO salary percentage | 20.7% |
| CEO tenure | 6.8yrs |
| CEO ownership | 3.4% |
| Management average tenure | 1.6yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CA$29m |
| Jun 30 2024 | n/a | n/a | -CA$23m |
| Mar 31 2024 | n/a | n/a | -CA$21m |
| Dec 31 2023 | CA$2m | CA$398k | -CA$16m |
| Sep 30 2023 | n/a | n/a | -CA$14m |
| Jun 30 2023 | n/a | n/a | -CA$13m |
| Mar 31 2023 | n/a | n/a | -CA$11m |
| Dec 31 2022 | CA$338k | CA$260k | -CA$11m |
| Sep 30 2022 | n/a | n/a | -CA$9m |
| Jun 30 2022 | n/a | n/a | -CA$18m |
| Mar 31 2022 | n/a | n/a | -CA$17m |
| Dec 31 2021 | CA$1m | CA$226k | -CA$16m |
| Sep 30 2021 | n/a | n/a | -CA$13m |
| Jun 30 2021 | n/a | n/a | -CA$2m |
| Mar 31 2021 | n/a | n/a | -CA$2m |
| Dec 31 2020 | CA$192k | CA$192k | -CA$2m |
| Dec 31 2019 | CA$180k | CA$180k | -CA$2m |
Compensation vs Market: Frank's total compensation ($USD1.34M) is above average for companies of similar size in the German market ($USD469.16K).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
CEO
Frank Gleeson (69 yo)
6.8yrs
Tenure
CA$1,926,547
Compensation
Mr. Francis Gleeson, also known as Frank, B.B.A., M.B.A., is a Co-Founder of Satellos Bioscience Inc. He serves as Chief Executive Officer of Satellos Bioscience Inc. since March 2018. He serves as Directo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | CA$1.93m | 3.35% € 2.2m | |
| CFO & Corporate Secretary | 1.3yrs | CA$741.42k | 0.035% € 22.7k | |
| Chief Scientific Officer | 1.9yrs | CA$1.45m | no data | |
| Executive Director | 3.3yrs | CA$216.74k | 1.5% € 970.2k | |
| Head of Corporate Strategy | 1.3yrs | CA$444.38k | no data | |
| Chief Business Officer | 1.3yrs | CA$745.80k | 0.0037% € 2.4k | |
| Co-Founder & Chief Discovery Officer | no data | CA$120.00k | 2.72% € 1.8m | |
| Senior Vice President of Finance & Administration | 3.3yrs | no data | 0.070% € 45.4k | |
| Strategic Advisor | 3.3yrs | CA$44.48k | no data | |
| Chief of Staff | no data | no data | no data | |
| Senior Vice President of Clinical Development Operations | 1.1yrs | no data | no data | |
| Senior Vice President of Medical & Scientific Affairs | less than a year | no data | no data |
1.6yrs
Average Tenure
63yo
Average Age
Experienced Management: 0ITA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.4yrs | CA$1.93m | 3.35% € 2.2m | |
| Executive Director | 3.3yrs | CA$216.74k | 1.5% € 970.2k | |
| Independent Director | 1.5yrs | CA$47.41k | 6.64% € 4.3m | |
| Independent Chairman of the Board of Directors | 6.4yrs | CA$87.84k | 0.22% € 144.2k | |
| Independent Director | 3.3yrs | CA$68.27k | 0.022% € 14.2k | |
| Independent Director | 6.8yrs | no data | 1.3% € 838.3k | |
| Independent Director | 3yrs | CA$93.58k | no data | |
| Chair of Clinical Advisory Board & Chief Medical Advisor | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Independent Director | 3yrs | CA$69.28k | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data |
3.0yrs
Average Tenure
62yo
Average Age
Experienced Board: 0ITA's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 14:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Satellos Bioscience Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Yu He | H.C. Wainwright & Co. |
| David Bautz | Zacks Small-Cap Research |